{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:49:09Z","timestamp":1785880149302,"version":"3.56.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013941","name":"CIBERDEM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.molmed.2026.05.008","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:36:56Z","timestamp":1781325416000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The emerging role of PPARs in primary biliary cholangitis"],"prefix":"10.1016","author":[{"given":"Xavier","family":"Palomer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rodr\u00edguez-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Garc\u00eda-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Wahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7138-8207","authenticated-orcid":false,"given":"Manuel","family":"V\u00e1zquez-Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2026.05.008_bb0005","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2026.05.008_bb0010","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","article-title":"APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis","volume":"16","author":"You","year":"2022","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.molmed.2026.05.008_bb0020","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jhep.2018.08.020","article-title":"Primary biliary cholangitis: a tale of epigenetically-induced secretory failure?","volume":"69","author":"Rodrigues","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13543784.2025.2573638","article-title":"An update on novel investigational agents for the treatment of primary biliary cholangitis","volume":"34","author":"Floreani","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.molmed.2026.05.008_bb0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12016-025-09074-x","article-title":"The treatment of primary biliary cholangitis: time for personalized medicine","volume":"68","author":"Men","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0040","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0045","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0050","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0092-8674(00)80726-6","article-title":"A unified nomenclature system for the nuclear receptor superfamily","volume":"97","author":"Nuclear Receptors Nomenclature Committee","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.05.008_bb0055","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000612","article-title":"PPAR agonists for the treatment of cholestatic liver diseases: over a decade of clinical progress","volume":"9","author":"Hayes","year":"2025","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.molmed.2026.05.008_bb0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.tem.2016.02.008","article-title":"Unraveling the effects of PPAR\u03b2\/\u03b4 on insulin resistance and cardiovascular disease","volume":"27","author":"Vazquez-Carrera","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2026.05.008_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: old and new tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.molmed.2026.05.008_bb0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0075","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/HEP.0000000000001225","article-title":"The immunological landscape of primary biliary cholangitis: mechanisms and therapeutic prospects","volume":"82","author":"Ronca","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0080","doi-asserted-by":"crossref","DOI":"10.12998\/wjcc.v13.i30.109028","article-title":"Advancing the management of primary biliary cholangitis: from pathogenesis to emerging therapies","volume":"13","author":"Curto","year":"2025","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.molmed.2026.05.008_bb0085","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.3748\/wjg.v29.i37.5292","article-title":"New insights into the pathogenesis of primary biliary cholangitis asymptomatic stage","volume":"29","author":"Reshetnyak","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0090","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cld.2022.06.003","article-title":"Immunologic responses and the pathophysiology of primary biliary cholangitis","volume":"26","author":"Chen","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.molmed.2026.05.008_bb0095","article-title":"Peroxisome proliferator-activated receptors regulate hepatic immunity and assist in the treatment of primary biliary cholangitis","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcpt.13971","article-title":"The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism","volume":"134","author":"Sun","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0105","doi-asserted-by":"crossref","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2026.05.008_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.molmed.2026.05.008_bb0115","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.05.008_bb0120","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1111\/bph.13928","article-title":"Inhibition of JNK signalling mediates PPAR\u03b1-dependent protection against intrahepatic cholestasis by fenofibrate","volume":"174","author":"Dai","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102056","article-title":"Selective PPAR\u03b4 agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway","volume":"298","author":"Kouno","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2026.05.008_bb0130","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.molmed.2026.05.008_bb0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0145","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000646","article-title":"Peroxisome proliferator-activated receptor delta and liver diseases","volume":"9","author":"Yamazaki","year":"2025","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.molmed.2026.05.008_bb0150","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/bph.14886","article-title":"Rosiglitazone alleviates intrahepatic cholestasis induced by \u03b1-naphthylisothiocyanate in mice: the role of circulating 15-deoxy-\u039412,14-PGJ2 and Nogo","volume":"177","author":"Zhang","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0155","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.bbalip.2019.05.014","article-title":"Hepatocyte peroxisome proliferator-activated receptor \u03b1 regulates bile acid synthesis and transport","volume":"1864","author":"Xie","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.molmed.2026.05.008_bb0160","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.26894","article-title":"Peroxisome proliferator-activated receptor \u03b1 activates human multidrug resistance transporter 3\/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion","volume":"59","author":"Ghonem","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0165","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep4.1787","article-title":"Adjunct fenofibrate up-regulates bile acid glucuronidation and improves treatment response for patients with cholestasis","volume":"5","author":"Gallucci","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.molmed.2026.05.008_bb0170","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.molmed.2026.05.008_bb0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-022-00687-7","article-title":"Mechanisms of pruritus in cholestasis: understanding and treating the itch","volume":"20","author":"Beuers","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0180","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40265-021-01521-1","article-title":"IL-31 inhibition as a therapeutic approach for the management of chronic pruritic dermatoses","volume":"81","author":"Roh","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.molmed.2026.05.008_bb0185","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.molmed.2026.05.008_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"Kremer","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/HEP.0000000000000791","article-title":"PPAR\u03b1, PPAR\u03b4, or both-that is the question!","volume":"80","author":"Wolters","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0205","article-title":"Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0210","doi-asserted-by":"crossref","first-page":"737","DOI":"10.21037\/atm-20-5110","article-title":"The role of bile acids in cholestatic liver injury","volume":"9","author":"Cai","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.molmed.2026.05.008_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.molmed.2026.05.008_bb0220","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0225","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2045-3701-2-34","article-title":"GW501516-activated PPAR\u03b2\/\u03b4 promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation","volume":"2","author":"Kostadinova","year":"2012","journal-title":"Cell Biosci."},{"key":"10.1016\/j.molmed.2026.05.008_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117303","article-title":"PPAR\u03b2\/\u03b4 attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells","volume":"179","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.molmed.2026.05.008_bb0240","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0245","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12876-025-03821-2","article-title":"Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Saeedian","year":"2025","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0250","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.05.008_bb0255","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0260","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","article-title":"Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: a randomized clinical trial","volume":"118","author":"Liu","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0265","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0270","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/apt.70574","article-title":"Long-term use of fenofibrate as second-line therapy in primary biliary cholangitis: a retrospective study","volume":"63","author":"Maxwell","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2026.05.008_bb0275","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0280","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000327","article-title":"A multicenter, open-label, single-arm study to evaluate the efficacy and safety of saroglitazar in patients with primary biliary cholangitis","volume":"12","author":"Vuppalanchi","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0285","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0290","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.05.008_bb0295","first-page":"S1","volume":"82","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.008_bb0300","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0305","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/apt.17755","article-title":"Open-label, clinical trial extension: two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis","volume":"59","author":"Mayo","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2026.05.008_bb0310","article-title":"Long-term efficacy and safety of selective PPAR\u03b4 agonist seladelpar in primary biliary cholangitis: ASSURE interim study results","author":"Levy","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.molmed.2026.05.008_bb0315","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.21037\/apm-21-1304","article-title":"Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis","volume":"10","author":"Shen","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.molmed.2026.05.008_bb0320","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000798","article-title":"High biochemical remission rates in patients with primary biliary cholangitis treated with \u201ctriple\u201d anticholestatic therapy","volume":"9","author":"Cancado","year":"2025","journal-title":"Hepatol. Commun."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:19:24Z","timestamp":1785878364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491426001334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":64,"alternative-id":["S1471491426001334"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2026.05.008","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging role of PPARs in primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2026.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}